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Incidence and Survival of Pediatric Soft Tissue Sarcomas:
Comparison between Adults and Children
Purpose
Pediatric-type sarcomas such as rhabdomyosarcoma (RMS), Ewing sarcoma (EWS),
primitive neuroectodermal tumor (PNET), and desmoplastic small round-cell tumor (DSRCT)
are rare in adults, with limited studies on their prognosis and optimal treatment strategies.
We aimed to examine the outcome of children and adult patients with RMS, EWS, PNET,
and DSRCT and relevant prognostic factors. 
Materials and Methods
We retrospectively reviewed 220 pediatric-type sarcoma patients at a single institution
between 1985 and 2011. Comparisons were made in order to examine differences in
demographics, disease characteristics, and survival. Survival analyses were performed using
the Kaplan-Meier method with log-rank tests and Cox proportional hazards models.  
Results
A total of 220 consecutive patients were identified at our institute. Median age was 15.6
years (range, 0 to 81 years) and there were 108 children (49%) and 112 adult patients
(51%). According to histological classification, 106 patients (48.2%) had RMS, 60 (27.3%)
had EWS, 50 (22.7%) had PNET, and 4 (1.8%) had DSRCT. With a median follow-up period
of 6.6 years, the estimated median overall survival (OS) of all patients was 75 months (95%
confidence interval [CI], 27.2 to 122.8 months) and median event-free survival (EFS) for all
patients was 11 months (95% CI, 8.8 to 13.2 months). No significant difference in OS and
EFS was observed between adults and children. In multivariate analysis, distant metastasis
(hazard ratio [HR], 1.617; 95% CI, 1.022 to 2.557; p=0.040) and no debulking surgery (HR,
1.443; 95% CI, 1.104 to 1.812; p=0.012) showed independent association with worse OS. 
Conclusion
Metastatic disease and no surgical treatment are poor prognostic factors for OS among
pediatric-type sarcomas for both adults and children.
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Introduction
Soft tissue sarcomas (STS) form a set of heterogeneous
neoplasms originating from mesenchymal cells. They are
rare tumors comprising approximately 1% of all adult
malignancies and 12% of pediatric cancers [1]. STS have
different tumor biology, clinical behavior, and response to
treatment, and some occur mainly in childhood, while others
are unusual in young children [2]. Some STS, including rhab-
domyosarcoma (RMS), Ewing sarcoma (EWS), primary
neuroectodermal tumor (PNET), and desmoplastic small
round cell tumor (DSRCT), are most common in children but
occur rarely in adults. However, risk of mortality and
morbidity is higher in adults with pediatric sarcoma with a
comparable diagnosis [3]. Due to the rarity of adult STS,
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information regarding its clinical and biological features is
limited; there is a lack of information on the survival of
adults with STS that occur in the pediatric population. 
RMS is the most frequent tumor in children, accounting for
more than 50% of cases [4]. Among three types of RMS
(alveolar, embryonal, and pleomorphic), pleomorphic RMS
is most common in adults, and tends to occur in the lower
extremity. The family of EWS includes EWS and PNET. The
majority of patients with EWS and PNET are younger than
30 years of age; they are small round-cell tumors consisting
of undifferentiated cellswith uniform nuclei and scanty
cytoplasm [5]. For patients with localized disease, survival
can be achieved for up to 70%; however, a relapse rate of up
to 30% has also been reported [6]. DSRCT is a rare but highly
aggressive mesenchymal tumor that develops in the abdom-
inal cavity of young male adults [7]. It usually develops in
adolescents and young adults (AYA), with a mean age at
diagnosis of approximately 22 years. The prognosis is
particularly poor, largely due to the fact that the majority of
patients present with metastatic disease. 
Previous studies on treatment outcome of pediatric-type
sarcoma reported controversial results on age as a predictor
of poor prognosis. A study comparing adult and pediatric
RMS from 1973 to 2005 reported that adults had worse
survival than children with similar tumors [3]. In pediatric
trials, older age has shown an association with worse
outcome, and unfavorable histology and distant metastasis
were more common in adults [8]. However, the prognosis
and optimal treatment strategies for the adult patient popu-
lation are still not conclusive.
In this study, we will compare features of four types of
pediatric sarcomas that occur in both adults and children,
characterize clinical outcome, and identify the prognostic
factors associated with survival. 
Materials and Methods
1. Study population
The clinical and survival outcome data of patients with a
reported diagnosis of RMS, EWS, PNET, and DSRCT
between 1985 and 2011 were obtained from the database at
Severance Hospital. All patients were treated with a multi-
disciplinary approach, including surgery, chemotherapy, or
radiotherapy. Clinical data of these patients were reviewed
retrospectively. The following clinical parameters were
collected: demographic data, pathology, primary anatomic
site, tumor extent at diagnosis, chemotherapy, radiotherapy,
surgery, recurrence or progression, and survival. The follow-
ing prognostic factors were analyzed: age, sex, tumor histol-
ogy, primary site, tumor extent, primary tumor size, surgery,
chemotherapy, and radiotherapy. Favorable tumor sites were
defined as nonparameningeal head and neck, genitourinary
sites except bladder and prostate, and orbit. Unfavorable
sites included the parameningeal head and neck region,
bladder, prostate, limb, and other sites. Tumor extent was
defined using the Intergroup Rhabdomyosarcoma Study
Group. 
2. Chemotherapy
Most study patients (90.4%) received chemotherapy and
the most common chemotherapy regimen was VP16/adri-
amycin/cyclophosphamide. Additional regimens included
combinations of adriamycin, ifosphamide, vincristine, acti-
nomycin-D, and cisplatin. 
3. Radiotherapy
Radiotherapy (RT) techniques and methods evolved with
technology over the course of the study; however, the basic
principles were applied to all patients as follows. Patients’
extremities were immobilized for simulation and treatment
in custom molds. The target volume encompassed the entire
affected compartment, but was longitudinally extended 5 to
8 cm beyond the tumor. If necessary, additional magnetic
resonance imaging was used for enhanced target definition.
Most patients received a consistent dose/fractionation sched-
ule of 50.4 Gy at 1.2 Gy fractions. The median RT dose was
45 Gy (range, 14 to 85 Gy).
4. Surgery
Debulking surgery, or wide excision, was performed in 129
patients (58.6%). Wide excision refers to a dissection plane
through unaffected normal tissue within the involved
compartment, as defined by the criteria of Enneking et al. [9].
5. Statistical analysis
Overall survival (OS) and event-free survival (EFS) were
estimated using the Kaplan-Meier method. OS was calcu-
lated from the date of diagnosis to the date of death from the
disease or the last follow-up. EFS was calculated from the
date of treatment to the first documented relapse or progres-
sion. Survival estimates were calculated using the Kaplan-
Meier method and log-rank test was used for comparison of
survival curves. The chi-squared test was used for compari-
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son of clinical parameters. Multivariate survival analyses
using a Cox’s proportional hazard model were performed in
order to characterize prognostic factors for OS and EFS.
Results
1. Clinical characteristics of pediatric sarcoma in children
and adults
Results of comparison of the clinical findings in children
and adult patients are shown in Table 1. A total of 220 pa-
Values are presented as number (%).
Table 1. Baseline characteristics of patients 
Characteristic Total (n=220) Children (n=108) Adults (n=112) p-value
Gender 0.010
Male 121 (55) 50 (46.3) 71 (63.4)
Female 99 (45) 58 (53.7) 41 (36.6)
Age 
Median age (range, yr) 15.6 (0-81) 6 (0-16) 26 (18-81)
Adult ( 18 yr) 112 (50.9) - -
 30 yr - - 43 (38.4)
< 30 yr - - 69 (61.6)
Child (< 18 yr) 108 (49.1) - -
Primary site 0.446
Favorable 69 (30.5) 34 (31.5) 35 (31.3)
Nonparameningeal 36 (16.4) 19 (17.6) 19 (17)
Genitourinary (nonbladder, nonprostate) 23 (10.5) 11 (10.2) 12 (10.7)
Orbit 8 (3.6) 4 (3.7) 4 (3.6)
Nonfavorable 151 (68.2) 74 (68.5) 77 (68.7)
Parameningeal 46 (20.9) 23 (21.3) 27 (20.5)
Bladder/prostate 9 (4.1) 5 (4.6) 5 (4.4)
Limb 46 (20.9) 21 (19.4) 25 (22.3)
Others 49 (22.3) 25 (23.1) 24 (21.4)
Tumor size (cm) 0.278
< 5 108 (49.1) 57 (52.8) 51 (46.4)
 5 108 (49.1) 49 (45.4) 59 (52.7)
Nonevaluable 4 (1.8) 2 (1.9) 2 (1.8)
Distant metastasis 0.446
M0 158 (71.8) 81 (75) 77 (68.8)
M1 59 (26.8) 26 (24.1) 33 (29.5)
Nonevaluable 3 (1.4) 1 (0.9) 2 (1.8)
Debulking surgery 0.482
Yes 129 (58.6) 61 (56.5) 39 (34.8)
No 82 (37.3) 43 (39.8) 68 (63.6)
Nonevaluable 9 (4.1) 4 (3.7) 5 (4.5)
Radiotherapy 118 (53.6) 55 (50.9) 63 (56.3) 0.687
Chemotherapy 199 (90.4) 99 (91.7) 100 (89.3) 1.000
Histopathology 0.381
Rhabdomyosarcoma 106 (48.2) 56 (51.8) 50 (44.6)
Ewing's sarcoma 60 (27.3) 30 (27.8) 30 (26.8)
Primary neuroectodermal tumor 50 (22.7) 18 (16.7) 32 (28.6)
Desmoplastic small round cell tumor 4 (1.8) 4 (3.7) 0 (0)
tients with a reported diagnosis of RMS, EWS, PNET, and
DSRCT were analyzed. The median age at the time of diag-
nosis was 15.6 years (range, 0 to 81 years). There were 108
pediatric patients (49%) and 112 adult patients (51%). There
was a statistically significant difference in the sex of patients:
there were more male than female patients in the adult
population (p=0.010). No differences in the baseline 
characteristics, except sex, were observed between children
and adults. More than half of the tumors in both children and
adults were located at unfavorable sites (68.5% and 68.7%).
A total of 158 patients (71.8%) presented with localized dis-
ease, 59 patients (26.8%) with metastatic disease and 3 
patients (1.4%) with unknown status. Tumor size was known
for 216 patients, with 108 patients (49.1%) having tumor size
less than 5 cm, and 108 patients (49.1%) having tumor size
equal to or greater than 5 cm. Patients with metastatic disease
had a higher proportion of large tumors than patients 
without metastatic disease (54% vs. 36.1%, p < 0.001). A total
of 129 patients (59%) underwent debulking surgery. Similar
rates of radiotherapy and chemotherapy were observed
among children and adults. According to histological 
classification, 106 (48.2%) had RMS, 60 (27.3%) had EWS, 50
(22.7%) had PNET, and 4 (1.8%) had DSRCT. 
For 108 children, with a median age of 6 years (range, 0 to
6 years), 74 patients (68.5%) had tumors located in unfavor-
able sites, 49 patients (45.4%) had tumor size equal to or
greater than 5 cm, and 26 patients (24.1%) had metastatic
disease. Sixty-one patients (56.5%) had undergone debulking
surgery, 55 patients (50.9%) had received radiotherapy, and
95 patients (87.9%) had received chemotherapy. By
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Table 2. Multivariate analysis of prognostic factors
All Children Adults
HR p-value HR p-value HR p-value
Gender
Male 1.00 1.00 1.00 
Female 1.023 (0.693-1.511) 0.908 1.001 (0.693-1.446) 0.995 1.000 (0.790-1.231) 0.999
Age 
Adult ( 18 yr) 1.00 - - - -
Child (< 18 yr) 1.051 (0.713-1.547) 0.802 - - - -
Primary site
Favorable 1.00 1.00 1.00 
Non-favorable 1.262 (0.751-1.798) 0.500 1.316 (0.695-2.491) 0.399 1.181 (0.702-1.763) 0.392
Tumor size (cm)
< 5 1.00 1.00 1.00 
 5 1.179 (0.766-1.813) 0.454 1.540 (1.06-2.24) 0.024 1.560 (0.798-3.050) 0.193
Distant metastasis
M0 1.00 1.00 1.00 
M1 1.617 (1.022-2.557) 0.040 1.851 (1.249-2.745) 0.001 1.261 (0.659-2.411) 0.484
Debulking surgery
Yes 1.00 1.00 1.00 
No 1.443 (1.104-1.812) 0.012 1.811 (1.467-1.958) 0.006 1.605 (1.349-1.910) 0.003
Chemotherapy
Yes 1.00 1.00 1.00 
No 1.009 (0.575-1.770) 0.975 1.243 (0.583-2.647) 0.573 1.279 (0.548-2.987) 0.570
Radiotherapy
Yes 1.00 1.00 1.00 
No 1.012 (0.696-1.471) 0.951 1.078 (0.626-1.858) 0.787 0.978 (0.582-1.642) 0.932
Histopathology 0.043 0.007 0.969
RMS 1.00 1.00 1.00 
EWS 1.300 (0.843-2.004) 0.236 1.756 (0.923-3.341) 0.086 0.955 (0.530-1.721) 0.879
PNET 1.562 (0.990-2.465) 0.055 2.387 (1.230-4.631) 0.010 1.023 (0.543-1.927) 0.944
DSRCT 1.560 (0.485-5.013) 0.456 2.523 (0.339-18.768) 0.366 1.063 (0.251-4.496) 0.934
HR, hazard ratio; RMS, rhabdomyosarcoma; EWS, Ewing sarcoma; PNET, primitive neuroectodermal tumor; DSCRT,
desmoplastic small round-cell tumor.
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histopathology, 56 patients (51.8%) had RMS, 30 (27.8%) had
EWS, 18 (16.7%) had PNET, and 4 (3.7%) had DSRCT. 
For 112 adults, with a median age of 26 years (range, 16 to
81 years), 77 patients (68.7%) had tumors located in unfavor-
able sites, 59 patients (52.7%) had tumor size equal to or
greater than 5 cm, and 33 patients (29.5%) had metastatic
disease. Thirty-nine patients (34.8%) had undergone debulk-
ing surgery, 63 patients (56.3%) had received radiotherapy,
and 100 patients (89.3%) had received chemotherapy. By
histopathology, 50 patients (44.6%) had RMS, 30 (26.8%) had
EWS, 32 (28.6%) had PNET, and none (0%) had DSRCT.
2. Follow-up and treatment outcome
Among 220 patients, 115 (52.3%) had died at the time of
analysis with a median follow-up period of 6.6 years (range,
0.1 to 29.0 years). Estimated median OS of all patients was
75 months (95% CI, 27.2 to 122.8 months), and the median
EFS of all patients was 11 months (95% CI 8.8 to 13.2 months).
No significant difference in OS was observed between adults
and children (60 months [95% CI, 1.9 to 132.1] vs. 75 months
[95% CI, 11.6 to 104.3], p=0.859) (Fig. 1A). In addition, no
difference in EFS was observed between adults and children
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Log-rank test, p=0.516
Fig. 1. (A) Comparison of overall survival (OS) in adults and children. (B) Comparison of event-free survival (EFS) in adults
and children. (C) Comparison of OS according to histology in all patients. (D) Comparison of EFS according to histology in
children. RMS, rhabdomyosarcoma; EWS, Ewing sarcoma; PNET, primitive neuroectodermal tumor; DSRCT, desmoplastic
small round-cell tumor. 
(9 months [95% CI, 9.4-14.6] vs. 11 months [95% CI, 5.1 to
18.9], p=0.516) (Fig. 1B). No significant difference in OS and
EFS was observed among patients with localized disease
only. The 5-year OS rates for RMS, PNET, EWS, and DSRCT
were 45%, 30%, 33%, and 0%, respectively. In comparison of
survival outcomes according to histology, a significant
difference in median OS was observed among the four
groups (not reached vs. 58 months [95% CI, 0 to 122.9] vs. 39
months [95% CI, 3.6 to 74.3] vs. 43 months [95% CI, 17.5 to
68.4], p=0.043) (Fig. 1C). In comparison of EFS among
children, a significant difference was still observed among
the four groups (not reached vs. 38 months [95% CI, 1.5 to
68.6] vs. 39 [95% CI, 6.4 to 89.6] vs. 43 [95% CI, 11.6 to 104.3],
p=0.007) (Fig. 1D). No significant difference in OS was
observed among adults according to histologic subtypes (not
shown). We then evaluated survival outcome of AYA popu-
lations only. The EFS of the AYA population was 12 months
(95% CI, 6.8 to 17.1 months) and that of the rest of the popu-
lation was 10 months (95% CI, 7.5 to 12.5 months). The OS of
the AYA population was 60 months (95% CI, 0 to 96.3
months) and that of the rest of the population was 77 months
(95% CI, 6.4 to 147.6 months). No significant difference in
both EFS and OS was observed between these two popula-
tions (Appendix 1A and B).
3. Analysis of prognostic factors
We performed univariate and multivariate analyses using
the log-rank test for analysis of prognostic factors in adults
and children (Table 2). In multivariate analysis, distant
metastasis (HR, 1.617; 95% CI, 1.022 to 2.557; p=0.040) and
no debulking surgery (HR, 1.443; 95% CI, 1.104 to 1.812;
p=0.012) showed independent association with worse OS. In
children, tumor size of more than 5cm (hazard ratio [HR],
1.540; 95% CI, 1.06 to 2.24; p=0.024), distant metastasis (HR,
1.851; 95% CI, 1.249 to 2.745; p=0.001), no debulking surgery
(HR, 1.811; 95% CI, 1.467 to 1.958; p=0.006), and PNET
histology (HR, 2.387; 95% CI, 1.230 to 4.631; p=0.010) showed
significant association with worse OS. In addition, PNET
showed an association with poor survival (HR, 2.387; 95%
CI, 1.230 to 4.631; p=0.010). For adults, no debulking surgery
(HR, 1.605; 95% CI, 1.349 to 1.910; p=0.003) was the only poor
prognostic factor of OS. In multivariate analysis among
adults, tumor size, distant metastasis, and histopathology
did not predict poor outcomes. 
Next, we compared OS of patients according to number of
poor prognostic factors. Poor prognostic factors were scored
as follows: no distant metastasis=0, distant metastasis=1;
tumor size less than 5 cm=0, tumor size equal or greater than
5 cm=1; surgery=0, no surgery=1. The Kaplan-Meier curve
of four stratified scores showed a significant difference in
survival (0 [not reached] vs. 1 [81 months] vs. 2 [58 months]
vs. 3 [18 months], p < 0.001) (Fig. 2). 
In a subgroup analysis of 158 patients with localized
disease, 52 patients (32.9%) showed recurrence: 21 patients
(13.3%) with local recurrence and 31 patients (19.6%) with
distant recurrence. The most frequent sites of distant
recurrence were lung (15%), brain (7%), bone (6%), spine
(2%), and liver (1%), in the order of frequency. 
Discussion
Using data during a 26-year period, we described 220 adult
and pediatric patients with a reported diagnosis of RMS,
EWS, PNET, and DSRCT. To the best of our knowledge, our
work represents the first study examining the survival and
prognostic factors in both pediatric and adult patients in the
Asian population. While there were no significant differences
in baseline characteristics in the study population, no signif-
icant differences in OS and EFS were observed between
adults and children. In children, large tumor size (> 5 cm),
metastatic disease, no surgical treatment, and PNET histol-
ogy showed an association with shorter OS, whereas in
adults, only no debulking surgery showed an association
with shorter OS. 
The effect of age on survival of sarcoma patients has been
a subject of debate, with different conflicting results from
different studies. In a few retrospective studies, survival in
adults was reported to be dramatically worse than that
14 CANCER  RESEARCH  AND  TREATMENT
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Fig. 2. Overall survival (OS) according to number of poor
prognostic factors. 
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reported for children [3,10,11]. Sultan et al. [3] reported that
adults with RMS had worse survival than children with
similar tumors. Lee et al. [12] reported that adults have fared
worse than children due to less aggressive treatments, and
fewer adults were treated with chemotherapy. However, in
recent studies, age was not found to be a predictor of poor
prognosis in adults [13,14]. In our study, we also did not
observe a difference in survival outcome among children and
adults. The differences in underlying tumor biology between
adults and children are not yet known. It may be that the
disease is more aggressive in adults, or that adults do not
respond favorably to the current treatment regimens [15].
Conduct of further clinical and molecular studies is
warranted in order to explain the possible differences
between adults and children. 
In the multivariate model, we compared prognostic factors
of survival between adults and children. In all patients,
surgical intervention was found to show significant associa-
tion with improved survival when compared with no
surgical intervention. Surgery is the mainstay of treatment
of STS, and the rate of local recurrence following wide resec-
tion with negative margins is usually below 20% [16].
However, 37.3% of patients did not undergo surgery due to
unresectability of the tumor and co-existing distant metas-
tases. In univariate analysis, adjuvant RT did not show
significant association with improved survival, consistent
with previous data indicating that RT improves local control,
but not OS [17]. Chemotherapy also did not show significant
association with improved survival, however, there are
issues to consider. Most patients received either adjuvant or
palliative chemotherapy, and only 21 patients (9.5%) did not
receive chemotherapy. It may be that there was not enough
power to make a meaningful comparison between those who
received chemotherapy and those who did not, or that
patients who did not receive chemotherapy had less aggres-
sive disease and better control with surgery alone. In
Table 3. Previously reported pediatric-type sarcoma in adults and children
Type No. Study years Results Reference
Western
RMS
Adults 1,071 1973-2005 Adults with RMS had significantly worse Sultan et al., 2009 [3]
Children 1,529 outcome than children, tumors were more likely to
be at unfavorable site; 5-year survival rate 27% vs. 61%
Adults 171 1975-2001 Overall rate of response to chemotherapy was 85%; Ferrari et al., 2003 [18]
5-year event-free survival was 28% and
5-year overall survival was 61%
Adults 113 5-Year survival rate 26% Ariel and Briceno, 1975 [19]
EWS/PNET
Age  14 190 1972-1992 Rate of relapse  14 years vs. >14 years: Bacci et al., 2004 [13]
Age > 14 212 15.9 vs. 13.8 (p < 0.94)
Adults Children 19 1995-2003 Median OS of patients  20 years vs. > 20 years Yamada et al., 2006 [14]
did not differ (p=0.27)
Adults 372 1989-2007 Adult age, hispanic race, metastatic disease, Lee et al., 2010 [12]
Children 353 large tumor size, low socioeconomic status are
poor prognostic factors for overall survival 
Adults 24 1990-2005 Localized disease: 3-year survival 59% Gupta et al., 2010 [20]
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Appendix 1. Comparison of event-free survival (EFS) (A) and overall survival (OS) (B) of adolescents and young adults (AYA)
population with the rest of the population.
